Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer

Alectinib, a novel alternative anaplastic lymphoma kinase (ALK) inhibitor, is highly effective against ALK-positive non-small cell lung cancer (NSCLC) and is well tolerated. Molecular targeted agents generally have little contribution to alopecia. We encountered a case of alopecia that developed gra...

Full description

Bibliographic Details
Main Authors: Tomonobu Koizumi, Toshirou Fukushima, Daisuke Gomi, Takashi Kobayashi, Nodoka Sekiguchi, Akiyuki Sakamoto, Shigeru Sasaki, Keiko Mamiya
Format: Article
Language:English
Published: Karger Publishers 2016-04-01
Series:Case Reports in Oncology
Subjects:
Anaplastic lymphoma kinase
Crizotinib
Hair loss
Brain metastasis
Online Access:http://www.karger.com/Article/FullText/445288
id doaj-838b3aba974041169ea956148e7a21cf
record_format Article
spelling doaj-838b3aba974041169ea956148e7a21cf2020-11-24T21:04:02ZengKarger PublishersCase Reports in Oncology1662-65752016-04-019121221510.1159/000445288445288Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung CancerTomonobu KoizumiToshirou FukushimaDaisuke GomiTakashi KobayashiNodoka SekiguchiAkiyuki SakamotoShigeru SasakiKeiko MamiyaAlectinib, a novel alternative anaplastic lymphoma kinase (ALK) inhibitor, is highly effective against ALK-positive non-small cell lung cancer (NSCLC) and is well tolerated. Molecular targeted agents generally have little contribution to alopecia. We encountered a case of alopecia that developed gradually over 2 months after initiation of alectinib administration for the treatment of ALK-positive NSCLC. The patient had no history of alopecia in previous treatments of cisplatin + pemetrexed and crizotinib. The present case indicates that alopecia should be taken into consideration as toxicity during alectinib treatment, which could adversely affect the psychological and emotional condition and quality of life even in patients treated with specific molecular targeted agents.http://www.karger.com/Article/FullText/445288Anaplastic lymphoma kinaseCrizotinibHair lossBrain metastasis
collection DOAJ
language English
format Article
sources DOAJ
author Tomonobu Koizumi
Toshirou Fukushima
Daisuke Gomi
Takashi Kobayashi
Nodoka Sekiguchi
Akiyuki Sakamoto
Shigeru Sasaki
Keiko Mamiya
spellingShingle Tomonobu Koizumi
Toshirou Fukushima
Daisuke Gomi
Takashi Kobayashi
Nodoka Sekiguchi
Akiyuki Sakamoto
Shigeru Sasaki
Keiko Mamiya
Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
Case Reports in Oncology
Anaplastic lymphoma kinase
Crizotinib
Hair loss
Brain metastasis
author_facet Tomonobu Koizumi
Toshirou Fukushima
Daisuke Gomi
Takashi Kobayashi
Nodoka Sekiguchi
Akiyuki Sakamoto
Shigeru Sasaki
Keiko Mamiya
author_sort Tomonobu Koizumi
title Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
title_short Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
title_full Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
title_fullStr Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
title_full_unstemmed Alectinib-Induced Alopecia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
title_sort alectinib-induced alopecia in a patient with anaplastic lymphoma kinase-positive non-small cell lung cancer
publisher Karger Publishers
series Case Reports in Oncology
issn 1662-6575
publishDate 2016-04-01
description Alectinib, a novel alternative anaplastic lymphoma kinase (ALK) inhibitor, is highly effective against ALK-positive non-small cell lung cancer (NSCLC) and is well tolerated. Molecular targeted agents generally have little contribution to alopecia. We encountered a case of alopecia that developed gradually over 2 months after initiation of alectinib administration for the treatment of ALK-positive NSCLC. The patient had no history of alopecia in previous treatments of cisplatin + pemetrexed and crizotinib. The present case indicates that alopecia should be taken into consideration as toxicity during alectinib treatment, which could adversely affect the psychological and emotional condition and quality of life even in patients treated with specific molecular targeted agents.
topic Anaplastic lymphoma kinase
Crizotinib
Hair loss
Brain metastasis
url http://www.karger.com/Article/FullText/445288
work_keys_str_mv AT tomonobukoizumi alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT toshiroufukushima alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT daisukegomi alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT takashikobayashi alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT nodokasekiguchi alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT akiyukisakamoto alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT shigerusasaki alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
AT keikomamiya alectinibinducedalopeciainapatientwithanaplasticlymphomakinasepositivenonsmallcelllungcancer
_version_ 1716772267676925952

Similar Items